Cypre's blog to discuss the latest movements in science.
We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data's implications for cytokine release syndrome.
Partner with Cypre to generate translational insights using our 3D tumor microenvironment organoid platform. From targeting the tumor or stroma, to modulating the immune system, we’re built for collaboration.
